Ftse Mib
38.831,13
-1,00%
DAX
22.679,73
-0,52%
S&P 500
5.956,06
0,01%
NASDAQ
19.075,26
0,26%
Bitcoin
86.338,40
2,70%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Compass Therapeutics Inc (CMPX) Compass Therapeutics Inc (CMPX) Notizie

CMPX

Compass Therapeutics (CMPX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CMPX
DataOraFonteTitoloSimboloCompagnia
19/02/202521:10AllPennyStocks.comMassachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price TargerNASDAQ:CMPXCompass Therapeutics Inc
13/02/202523:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMPXCompass Therapeutics Inc
12/02/202515:39Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CMPXCompass Therapeutics Inc
04/02/202521:45Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CMPXCompass Therapeutics Inc
29/01/202514:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceNASDAQ:CMPXCompass Therapeutics Inc
08/01/202518:15AllPennyStocks.comAnother Day, Another Biotech Stealing The ShowNASDAQ:CMPXCompass Therapeutics Inc
08/01/202514:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMPXCompass Therapeutics Inc
08/01/202514:00GlobeNewswire Inc.Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug CandidateNASDAQ:CMPXCompass Therapeutics Inc
10/12/202420:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CMPXCompass Therapeutics Inc
10/12/202414:00GlobeNewswire Inc.Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerNASDAQ:CMPXCompass Therapeutics Inc
02/12/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:CMPXCompass Therapeutics Inc
13/11/202414:30GlobeNewswire Inc.Compass Therapeutics to Participate in Upcoming Investor EventsNASDAQ:CMPXCompass Therapeutics Inc
12/11/202414:00GlobeNewswire Inc.Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
08/11/202416:05GlobeNewswire Inc.Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:CMPXCompass Therapeutics Inc
04/10/202416:31GlobeNewswire Inc.Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingNASDAQ:CMPXCompass Therapeutics Inc
09/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMPXCompass Therapeutics Inc
30/08/202423:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CMPXCompass Therapeutics Inc
12/08/202414:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CMPXCompass Therapeutics Inc
12/08/202414:00GlobeNewswire Inc.Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
07/08/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare ConferenceNASDAQ:CMPXCompass Therapeutics Inc
06/08/202414:00GlobeNewswire Inc.Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract CancerNASDAQ:CMPXCompass Therapeutics Inc
30/05/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:CMPXCompass Therapeutics Inc
28/05/202422:10GlobeNewswire Inc.Compass Therapeutics Announces CEO TransitionNASDAQ:CMPXCompass Therapeutics Inc
23/05/202423:05GlobeNewswire Inc.Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual MeetNASDAQ:CMPXCompass Therapeutics Inc
14/05/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:CMPXCompass Therapeutics Inc
13/05/202414:00GlobeNewswire Inc.Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
25/04/202414:00GlobeNewswire Inc.Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedNASDAQ:CMPXCompass Therapeutics Inc
16/04/202414:00GlobeNewswire Inc.Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid TumorsNASDAQ:CMPXCompass Therapeutics Inc
12/04/202414:00GlobeNewswire Inc.Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ConferenceNASDAQ:CMPXCompass Therapeutics Inc
10/04/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Stifel Targeted Oncology DaysNASDAQ:CMPXCompass Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CMPX

La tua Cronologia

AQSE
XLEP.GB
Invesco Energy S&P Us Se...
AQSE
RCN.GB
Redcentric
BIT
P13ZD7
BNP Paribas Issuance
BIT
UC7C67
Unicredit Bank
NYSE
NGL
NGL Energy Partners
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci